Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer.

[1]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Berlin,et al.  The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS) , 2008 .

[3]  N. Kipshidze,et al.  Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study. , 2007, Atherosclerosis.

[4]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[5]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[7]  C. Lindley,et al.  Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. , 2006, Clinical therapeutics.

[8]  C. Stefanadis,et al.  Advances in vulnerable plaque detection and treatment: how far have we gone? , 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[9]  D. Cunningham,et al.  Managing Patients Treated with Bevacizumab Combination Therapy , 2005, Oncology.

[10]  R. Maki,et al.  Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[14]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Qian,et al.  Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.

[16]  R. Dodge,et al.  The prognostic significance of angiogenesis in epithelial ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Sueishi,et al.  Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. , 1995, Human pathology.

[18]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[19]  M. Dimopoulos,et al.  Inhibition of angiogenesis: common theme for cancer and atheromatosis? , 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[20]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. J. Poole,et al.  The role of FGF and VEGF in angioblast induction and migration during vascular development , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.